This result indirectly supports the previous finding that the addition of venetoclax is not beneficial in TP53-mutated AML, though we consider that an interpretation of treatment outcomes from a phase I study should be cautious [80]. This evidence concerns the gene TP53 and acute myeloid leukemia.